The company adds new pouch strengths and formats to widen its smoke-free offerings for legal-age adults.
Philip Morris International's U.S. businesses announced the expansion of the ZYN oral nicotine portfolio. The company is adding 1.5 mg and 8 mg options to its flagship dry pouch line, complementing its existing 3 mg and 6 mg strengths.
The business also rolled out ZYN ULTRA, a higher-moisture oral pouch line that is free of tobacco leaf. The rollout follows marketing granted orders issued by the U.S. Food and Drug Administration in August 2026 for 11 ZYN ULTRA products, covering ten 9 mg variants and one 11 mg option. Previously, the agency issued modified risk tobacco product orders for 20 ZYN dry pouch products in June 2026.
In the fourth quarter, the company plans to transition its 3 mg and 6 mg dry pouch variants to 20 pouches per can. Domestic production takes place in Owensboro, Kentucky, and at a 148-acre, 780,000-square-foot facility in Aurora, Colorado, which began commercial manufacturing in July 2026.
Forty-five million legal-age Americans use nicotine. PMI U.S. is committed to expanding our range of less harmful smoke-free products so that no adult ever smokes another cigarette because they can't find a suitable alternative.
Newsletter
Markets in your inbox, weekly
LATAM-focused analysis, investing ideas, and the week in finance.
Keep reading
